Effects of Yishenbupi (tonifying-kidney and invigorating-spleen) prescription on the expression of renal fibrosis-associated proteins in unilateral ureteral occlusion rats

TMR Integrative Medicine

article

Jue-Ying Chen¹  Ji-Wei Qiu¹  Jun-Lin Mo¹  Chun-Li Long¹  Wei Shi¹  Yong-Xiang Xie¹ 

[1] Guangxi University of Chinese Medicine, Nanning 530001, China. 2First Affiliated Hospital of Guangxi University of Chinese Medicine

关键词: Renal interstitial fibrosis;    Yishenbupi prescription;    Vimentin;    α-SMA;    Fibronectin;   

DOI  :  10.12032/TMRIM202004013

学科分类：医学（综合）

来源: TMR publishing group

【 摘 要 】

Objective: To evaluate the effects and mechanism of the Yishenbupi (tonifying-kidney and invigorating-spleen)prescription on the expression of renal fibrosis-associated vimentin, α-SMA, and fibronectin in unilateral ureteralocclusion rats. Methods: A total of 48 SD (Sprague-Dawley) rats were randomly divided into the model, sham-operated (sham), irbesartan, and Yishenbupi groups, with 12 rats in each group. After the unilateral ureteralocclusion model was established, rats in the model and sham groups were administered normal saline, whereas ratsin the Yishenbupi group were administered Yishenbupi prescription (18 g/kg/d) intragastrically and those in theirbesartan group were administered irbesartan (10 mg/kg/d) intragastrically. All rats were sacrificed 21 days later. Pathological changes in rat renal tissue were evaluated by H&E staining. The expression of vimentin, α-SMA, andfibronectin in renal tissues was detected by western blotting. Results: Compared with the sham group the modelgroup had renal tubular epithelial cell atrophy, inflammatory cell infiltration accompanied with the proliferation ofinterstitial collagen fibers, fewer glomeruli, or glomerulosclerosis. Compared with the model group, significantlyless renal tubular and glomerular damages, inflammatory cell infiltration, and collagen fibers were observed indifferent intervention groups, especially in the Yishenbupi group. Compared with the sham group, significantlyhigher expressions of fibrosis markers, including vimentin, α-SMA, and fibronectin, were observed in the modelgroup. Compared with the model group, the expression of anti-fibrosis markers, including vimentin, α-SMA andfibronectin, was significantly decreased in both the irbesartan and Yishenbupi groups (P < 0.01); however, theYishenbupi group showed higher efficacy than the irbesartan group (P < 0.05). Conclusion: The Yishenbupiprescription may improve renal fibrosis by reducing the expression of fibrosis-associated vimentin, α-SMA, andfibronectin.

【 授权许可】

CC BY